65,437 trials
Major Depressive Disorder
Primary: Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline — 23.2; 22.4; 11.8; 13.2 Points on HAMD-17 scale — p=0.0119
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Cataracts
Primary: Uncorrected Distance Visual Acuity — 0.09 logMAR
Hemorrhage
Primary: Assessment of TachoSil® by the Surgeon With Respect to Handling, Utility and Satisfaction in the Operation, Documented Using 10 Point Numerical Rating Scales — 2.54…
Non-small Cell Lung Cancer
Primary: Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events — 3.2 Percentage of patients
The Methodology Assessment of Glucose Dependent Insulin Secretion
Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001
Attention Deficit Hyperactivity Disorder · Reading Disorder
Primary: Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm — 299.90; 308.82; 265.61; 260.51 milliseconds (msec) — p=0.504
Smoking
Primary: Percent Mean Change in Blood Oxygen-level Dependent (BOLD) Scores During Rapid Visual Information Processing (RVIP) Task — 0.0; 0.2; 0.7; 0.7 Percentage change in BOLD…
Pulmonary Embolism · Venous Thromboembolism
Primary: Major Adverse Event — 0; 1; 2; 0 participants
Morbid Obesity
Primary: Excess Weight Loss From Pre-operation to 5 Years Post-operation — 68.4; 45.4 percent change
Pulmonary Disease, Chronic Obstructive
Primary: Number of Patients With Adverse Events (AEs) — 71 Participants
Seasonal Allergic Rhinitis
Primary: Changes in the Total Nasal Symptom Severity Score (TNSS) at 6 Hours After Dosage Administration on Day 1 — -2.01; -1.86 score on a scale — p=0.625
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 — -0.71; 0.31 Percent — p=<0.001
Diphtheria · Pertussis · Haemophilus Infection
Primary: Number of Participants Who Had Positive Response to the Solicited Adverse Events Questionnaire Post 4th Dose of the Pentacel® Vaccination Series — 3023; 161; 149; 6…
Glioblastoma
Primary: Median Progression Free Survival After Primary Surgical Treatment, Concomitant and Adjuvant Chemotherapy With Temozolomide, for Patients With Newly Diagnosed…